From: Government use licenses in Thailand: an assessment of the health and economic impacts
Parameters | Values | References |
---|---|---|
Thai Gross Domestic Product (GDP) per capita (Baht) | 135,220 | [43] |
Disability Adjusted Life Years (DALYs) averted from EFV-based ARVs treatment | 5.69 | [44] |
DALYs averted from NVP-based ARVs treatment | 5.54 | Â |
QALYs gained from LPV/r-based ARVs treatment | No-data | - |
QALYs gained from indinavir/ritonavir (IDV/r)-based ARVs treatment | No-data | - |
QALYs gained from clopidogrel plus aspirin, which is used for secondary prevention of ischemic heart disease | 7.37 | [45] |
QALYs gained from aspirin alone, which is used for secondary prevention of ischemic heart disease | 7.31 | Â |
QALYs gained from letrozole for treatment of breast cancer | 13.14 | [46] |
QALYs gained from tamoxifen for treatment of breast cancer | 12.73 | Â |
QALYs gained from docetaxel for treatment of breast cancer | 0.87 | [47] |
QALYs gained from paclitaxel for treatment of breast cancer | 0.66 | Â |
QALYs gained from docetaxel for treatment of lung cancer | 0.41 | [48] |
QALYs gained from pemetrexed for treatment of lung cancer | 0.41 | Â |
QALYs gained from erlotinib for treatment of lung cancer | 0.42 | [48] |
QALYs gained from imatinib for treatment of Chronic Myeloid Leukemia (CML) | 1.07 | [49] |
QALYs gained from imatinib for treatment of GIST | 1.9 | [50] |